No influence of body weight on pregnancy rate in patients treated with cetrorelix according to the single- and multiple-dose protocols

Reproductive BioMedicine Online

Volumn 6, Issue 4, 2003, Pages 482-487

  Engel, Jörg Bernhard ^a,f   Ludwig, Michael ^b   Junge, K ^c,d   Howles, C M ^e   Diedrich, K ^a  

^a University Clinic of Luebeck   (Germany)

^b ENDOKRINOLOGIKUM HAMBURG   (Germany)

^c Zentaris GmbH   (Germany)

^d Baxter Oncology GmbH   (Germany)

^e Serono International SA   (Switzerland)

^f HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Body weight; Cetrorelix; Plasma concentration; Pregnancy rate

Indexed keywords

CETRORELIX; CHORIONIC GONADOTROPIN; GONADORELIN ANTAGONIST; HUMAN MENOPAUSAL GONADOTROPIN; RECOMBINANT FOLLITROPIN;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BODY WEIGHT; CELL COUNT; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; CUMULUS OOPHORUS; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; MAJOR CLINICAL STUDY; MULTIPLE DRUG DOSE; OOCYTE; OVARY FOLLICLE; PREGNANCY RATE; SINGLE DRUG DOSE; STATISTICAL MODEL;

EID: 0038575241     PISSN: 14726483     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-6483(10)62171-2     Document Type: Article

References (28)

1. Albano C, Smitz J, Camus M et al. 1997 Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertility and Sterility 67, 917-922.
2. Albano C, Felberbaum RE, Smitz J et al. 2000 Controlled ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the LHRH-antagonist cetrorelix (Cetrotide) and the LHRH-agonist buserelin. Human Reproduction 15, 526-531.
3. Chillik C, Acosta A 2001 The role of LHRH agonists and antagonists. Reproductive BioMedicine Online 2, 120-128.
4. De Greef H, Mannaerts B, Oreleman E 2001 Gonadotropin Releasing Hormone Antagonist. Patent application WO 01-00227.
5. Diedrich K, Diedrich C, Santos E et al. 1994 Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Human Reproduction 9, 788-791.
6. Diedrich K, Frydman R, Felberbaum RE et al. 2001 Comment on the debate article. Embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 16, 1305-1306.
7. Duijkers IJ, Klipping C, Willemsen WN et al. 1998 Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist cetrorelix in healthy female volunteers. Human Reproduction 13, 2392-2398.
8. Erb K, Klipping C, Duijkers I et al. 2001 Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women. Fertility and Sterility 75, 316-323.
9. Felberbaum RE, Diedrich K 2003 Gonadotrophin-releasing hormone antagonists: will they replace the agonists? Reproductive BioMedicine Online 6, 43-53.
10. Felberbaum RE, Albano C, Ludwig M et al. 2000 Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the LHRH-antagonist cetrorelix (Cetrotide®) according to the multiple dose protocol - results of a prospective non-controlled phase III study. Human Reproduction 15, 1015-1020.
11. Hamm W 2001 Broad experience with Cetrotide (cetrorelix) - results of a large multinational phase IIIB study. VIth International Symposium on GnRH-Analogues in Cancer and Human Reproduction, Geneva, Switzerland.
12. Hardy RI, Tummon IS, Hosseinzadeh M et al. 2001 Luteinizing hormone (LH) surge on ganirelix (Antagon) is related to body mass index (BMI). Fertility and Sterility 73, 178-179.
13. Hernandez ER 2000. Embryo implantation and GnRH antagonists. Embryo implantation: the Rubicon for GnRH antagonists. Human Reproduction 15, 1211-1216.
14. Howles C 2002 The place of gonadotrophin-releasing hormone antagonists in reproductive medicine. Reproductive BioMedicine Online 4 (suppl. 1), 64-71.
15. Lashen H, Ledger W, Bernal AL, Barlow D 1999 Extremes of body mass do not adversely affect the outcome of superovulation and in-vitro fertilization. Human Reproduction 14, 712-715.
16. Ludwig M, Felberbaum RE, Devroey P et al. 2000 Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist cetrorelix in controlled ovarian stimulation for assisted reproduction. Archives of Gynecology and Obstetrics 264, 29-32.
17. Ludwig M, Albano C, Olivennes F et al. 2001a Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide®) in controlled ovarian stimulation for IVF. Archives of Gynecology and Obstetrics 266, 12-17.
18. Ludwig M, Katalinic A, Diedrich K 2001b Use of GnRH antagonists in ovarian stimulation for ART compared to the long protocol: a meta-analysis. Archives of Gynecology and Obstetrics 265, 175-182.
19. Ludwig M, Katalinic A, Banz C et al. 2002a Tailoring the GnRH antagonist cetrorelix acetate to individual patients' needs in ovarian stimulation for IVF: results of a prospective, randomized study. Human Reproduction 17, 2842-2845.
20. Ludwig M, Katalinic A, Felberbaum RE, Diedrich K 2002b Safety aspects of GnRH antagonists in ovarian stimulation procedures: ovarian hyperstimulation syndrome and health of children born. Reproductive BioMedicine Online 5 (suppl. 1), 61-67.
21. Oberye JJ, Mannaerts BM, Huisman JA, Timmer CJ 1999a Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertility and Sterility 72, 1006-1012.
22. Oberye JJ, Mannaerts BM, Kleijn HJ, Timmer CJ 1999b Pharmacokinetic and pharmacodynamic characteristics of ganirelix (antagon/orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertility and Sterility 72, 1001-1005.
23. Olivennes F 2002 GnRH antagonists: do they open new pathways to safer treatment in assisted reproductive techniques? Reproductive BioMedicine Online 5 (suppl. 1), 20-25.
24. Olivennes F, Fanchin R, Bouchard Ph et al. 1994 The single or dual administration of the GnRH antagonist cetrorelix prevents premature LH surges in an IVF-ET program. Fertility and Sterility 62, 468-476.
25. Olivennes F, Alvarez S, Bouchard P et al. 1998 The use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg. Human Reproduction 13, 2411-2414.
26. Olivennes F, Belaisch-Allart J, Emperaire JC et al. 2000 A prospective randomized controlled study in IVF-ET with a single dose of a LH-RH antagonist (cetrorelix) or a depot formula of a LH-RH agonist (triptorelin). Fertility and Sterility 73, 314-320.
27. Seelig AS, al. Hasani S, Katalinic A et al. 2002 Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertility and Sterility 77, 472-475.
28. Wittemer C, Ohl J, Bailly M et al. 2000 Does body mass index of infertile women have an impact on IVF procedure and outcome? Journal of Assisted Reproduction and Genetics 17, 547-552.